Scholar Rock (SRRK) reported third-quarter 2026 net product revenue of $0.6 million from U.S. sales of ISEMBYLD and a net loss of $107.2 million, or $0.81 per basic and diluted share.
The company said ISEMBYLD received FDA approval on September 11, 2026, and that it entered a definitive agreement in November to sell its Rare Pediatric Disease Priority Review Voucher for $205 million, subject to closing conditions.
- Cash, cash equivalents and marketable securities totaled $413.6 million as of September 30, 2026.
- ISEMBYLD was shipped to the specialty network before quarter-end, with initial patients infused in October.
- Scholar Rock resubmitted its European application for apitegromab, with a CHMP opinion expected in the first half of 2027.
- The company said its Japanese apitegromab application was accepted under priority review.
$SRRK Insider Trading Activity
$SRRK insiders have traded $SRRK stock on the open market 19 times in the past 6 months. Of those trades, 6 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $SRRK stock by insiders over the last 6 months:
- SRINIVAS AKKARAJU has made 6 purchases buying 289,470 shares for an estimated $11,999,922 and 0 sales.
- KATIE PENG has made 0 purchases and 3 sales selling 5,446 shares for an estimated $293,404.
- JEFFREY S. FLIER has made 0 purchases and 3 sales selling 3,053 shares for an estimated $164,490.
- JOSHUA REED has made 0 purchases and 2 sales selling 3,053 shares for an estimated $164,067.
- KRISTINA BUROW has made 0 purchases and 2 sales selling 3,053 shares for an estimated $164,063.
- MICHAEL GILMAN has made 0 purchases and 3 sales selling 2,544 shares for an estimated $137,057.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SRRK Hedge Fund Activity
We have seen 183 institutional investors add shares of $SRRK stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- REDMILE GROUP, LLC removed 4,755,529 shares (-52.5%) from their portfolio in Q2 2026, for an estimated $261,554,095
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 2,607,348 shares (+inf%) to their portfolio in Q2 2026, for an estimated $143,404,140
- BLACKROCK, INC. added 2,024,791 shares (+27.1%) to their portfolio in Q2 2026, for an estimated $111,363,505
- ORBIS ALLAN GRAY LTD added 1,753,550 shares (+42.0%) to their portfolio in Q2 2026, for an estimated $96,445,250
- VESTAL POINT CAPITAL, LP removed 1,324,422 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $72,843,210
- MORGAN STANLEY added 1,319,749 shares (+602.6%) to their portfolio in Q2 2026, for an estimated $72,586,195
- SIREN, L.L.C. removed 1,250,000 shares (-11.5%) from their portfolio in Q2 2026, for an estimated $68,750,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.